SAVA Cassava Sciences Inc.

5.61
-0.33  -6%
Previous Close 5.94
Open 5.54
Price To Book 5.55
Market Cap 96,600,273
Shares 17,219,300
Volume 1,443,486
Short Ratio
Av. Daily Volume 5,098,955
Stock charts supplied by TradingView

NewsSee all news

  1. Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimer's Disease (JPAD)

    AUSTIN, Texas, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that The Journal of Prevention of

  2. Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer's Disease

    AUSTIN, Texas, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced it has initiated dosing for the last patient

  3. Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer's Disease at CTAD 2019

    - New Data Shows Clinical Evidence of Target Engagement and Target Validation – - Company Expects Data Publication in a Peer-reviewed Medical Journal – AUSTIN, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cassava

  4. Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results

    - Phase 2a Study Showed Statistically Significant Decreases (p<0.001) in Clinical Biomarkers of Alzheimer's Disease - - Phase 2b Study in Patients with Alzheimer's Disease Initiated in Multiple Clinical Sites - -

  5. Cassava Sciences' Clinical Results in Alzheimer's Selected as Late-Breaking News at CTAD 2019

    AUSTIN, Texas, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that clinical results of its Phase 2a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b completion of enrolment announced January 28, 2020, with top-line data due mid-2020.
PTI-125
Alzheimer’s disease

Latest News

  1. Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimer's Disease (JPAD)

    AUSTIN, Texas, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that The Journal of Prevention of

  2. Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer's Disease

    AUSTIN, Texas, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced it has initiated dosing for the last patient

  3. Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer's Disease at CTAD 2019

    - New Data Shows Clinical Evidence of Target Engagement and Target Validation – - Company Expects Data Publication in a Peer-reviewed Medical Journal – AUSTIN, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cassava

  4. Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results

    - Phase 2a Study Showed Statistically Significant Decreases (p<0.001) in Clinical Biomarkers of Alzheimer's Disease - - Phase 2b Study in Patients with Alzheimer's Disease Initiated in Multiple Clinical Sites - -

  5. Cassava Sciences' Clinical Results in Alzheimer's Selected as Late-Breaking News at CTAD 2019

    AUSTIN, Texas, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that clinical results of its Phase 2a

  6. Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer's Patients

    First two patients dosed with lead drug candidate, PTI-125 Study initiation follows positive Phase 2a results demonstrating 100% response rate AUSTIN, Texas, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.

  7. Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer's Patients

    Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p<.001) Clinical data support initiation of a Phase 2b study in Alzheimer's in Q3